{
    "nctId": "NCT05191914",
    "briefTitle": "Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors",
    "officialTitle": "Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to Cyclin-dependent Kinases\uff08CDK\uff094/6 Inhibitors",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* age \u2265 18 years, postmenopausal \\* female patients;\n* histologically or cytologically confirmed hormone receptor positive (ER positive, PR positive or negative), human epidermal growth factor receptor 2 negative # breast cancer patients;\n* the disease before enrollment is overall unresectable locally advanced or metastatic breast cancer, and at least one measurable lesion or no measurable lesion and bone metastasis alone patients;\n* for locally advanced or metastatic breast cancer, previous progression by first-line aromatase inhibitors combined with Cyclin-dependent kinases\uff08CDK\uff094/6 inhibitors;\n* the total number of regimens regardless of rescue therapy or adjuvant therapy before enrollment is \u2264 3, of which the number of rescue chemotherapy regimens is \u2264 1;\n* Eastern Collaborative Oncology Group\uff08ECOG\uff09 score 0-1;\n* absolute neutrophil count \u2265 1.5 \u00d7 109/L, platelets \u2265 100 \u00d7 109/L, hemoglobin \u2265 90 g/L;\n* expected survival time \u2265 3 months;\n* Voluntarily participate in this clinical trial and sign the written informed consent form\n\nExclusion Criteria:\n\n* no measurable lesions (except simple bone metastasis), such as pleural or pericardial exudate, ascites, etc.;\n* underwent major surgical procedures or significant trauma before enrollment, or patients are expected to undergo major surgical treatment;\n* Patients who have previously been treated with fulvestrant or histone deacetylase inhibitors (including romidepsin, vorinostat), but have received only one cycle (\u2264 2 times, d1, d15, respectively) of fulvestrant within 28 days (before enrollment) are allowed;\n* known to have a history of allergy to the drug components of this protocol;\n* the presence of brain (membrane) metastasis during the screening period;\n* a history of immunodeficiency, including HIV test positive, or suffering from other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;\n* uncontrolled important cardiovascular disease;\n* abnormal liver function \\[total bilirubin \\> 1.5 times the upper limit of normal; alanine aminotrans\uff08ALT\uff09/aspartate aminotransferase\uff08AST\uff09 \\> 2.5 times the upper limit of normal in patients without liver metastasis, alanine aminotrans\uff08ALT\uff09/aspartate aminotransferase\uff08AST\uff09 \\> 5 times the upper limit of normal in patients with liver metastasis\\], abnormal renal function (serum creatinine \\> 1.5 times the upper limit of normal);\n* pregnant, lactating female patients or women of childbearing potential baseline pregnancy test positive; or during the study and the last dose of at least 8 to take effective contraceptive measures in subjects of childbearing age;\n* According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study (such as: severe hypertension, diabetes, thyroid disease, active infection, etc.);\n* History of definite neurological or psychiatric disorders, including epilepsy or dementia;\n* Unsuitable for participation in the study as judged by the investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}